Number of patients | BB | CCB | P value | ||
26 | 26 | ||||
Aspirin | 92% | 24 | 96% | 25 | 1 |
Clopidogrel | 92% | 24 | 96% | 25 | 1 |
Anticoagulation use | 0% | 0 | 8% | 2 | |
Warfarin | 0% | 0 | 4% | 1 | 1 |
Rivaroxaban | 0% | 0 | 4% | 1 | 1 |
ACEi/ARB | 42% | 11 | 46% | 12 | 1 |
BB | 77% | 20 | 12% | 3 | <0.001 |
Carvedilol | 0% | 0 | 4% | 1 | |
Bisoprolol | 73% | 19 | 4% | 2 | |
Propranolol | 4% | 1 | 0% | 0 | |
CCB | |||||
Amlodipine | 15% | 4 | 77% | 20 | <0.001 |
Statin | 85% | 22 | 73% | 19 | 0.42 |
Atorvastatin | 12% | 3 | 15% | 4 | |
Pitavastatin | 19% | 5 | 12% | 3 | |
Pravastatin | 4% | 1 | 0% | 0 | |
Rosuvastatin | 50% | 13 | 46% | 12 | |
Other lipid-lowering agents | 4% | 1 | 12% | 3 | 0.70 |
Values are mean_SD or n (%).
ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker ; BB, beta blocker; CCB, calcium channel blocker.